Loading patent…
AssigneeSt. Jude Children's Research Hospital
InventorsCaitlin Zebley, Hossam Abdelsamed, Benjamin Youngblood
Estimating the term…
Provided herein are methods and compositions for modulating T-cell activity by incubating a CD8 T cell with a signal 3 cytokine, such as IL-12. Incubation of naïve CD8 T cells, particularly, with a signal 3 cytokine can acquire long-lived memory associated gene expression characteristic of the stem cell memory subset of CD8 T cells. Further, incubation with signal 3 cytokines can induce changes to the epigenetic profile of naïve CD8 T cells that are more characteristic of bona fide Tscm cells than in vitro generated cells using traditional differentiation protocols. On account of epigenetic profiles being preserved during in vivo homeostasis, signal 3 cytokines such as IL-12 can be used to engineer a T cell population with the desired epigenetic profile that maintains effector functions and proliferative capacity.
A method for modulating the activity of at least one CD8 T cell obtained from a mammal, the method comprising:
A method for selecting a subset of CD8 T cells comprising
A population of CD8 T cells comprising at least 60% CD8 T cells having an enhanced effector response when compared to a control CD8 T cell.
A method of treating a chronic infection or cancer in a subject, said method comprising:
Use of a signal 3 cytokine for enhancing the effector potential of a CD8 T cell comprising incubating a CD8 T cell in the presence of said signal 3 cytokine.
Use of a CD8 T cell having enhanced effector potential in the treatment of a chronic infection or cancer in a subject, wherein said CD8 T cell was incubated in the presence of a signal 3 cytokine.
Use of a CD8 T cell having enhanced effector potential in the manufacture of a medicament for the treatment of a chronic infection or cancer in a subject, wherein said CD8 T cell was incubated in the presence of a signal 3 cytokine.
Dependencies are inferred from the claim text.